Montelukast Tillomed Laboratories

Montelukast, the active ingredient in Montelukast Tillomed Laboratories, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Tillomed Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions. - Asthma: reduces the frequency of asthma attacks and improves overall breathing control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic triggers. - Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of queasiness. - Dizziness: transient light‑headedness. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat. - Mood changes: depression, anxiety or suicidal thoughts. - Severe allergic reaction: rash, itching, or hives. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering and detachment.

When prescribing Montelukast, consider the following safety measures. - Pregnancy: Category B; use only if the potential benefit justifies the potential risk to the fetus. - Lactation: monitor infant for possible adverse effects; benefits and risks should be weighed. - Liver disease: assess hepatic function and adjust therapy if needed. - Elderly patients: start at the lowest effective dose and monitor for side effects. - Drug interactions: review concomitant medications for potential interactions. - Store at room temperature: keep in the original packaging, protect from moisture and excessive heat.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Ritonavir: may increase montelukast plasma concentrations. - Phenobarbital: may reduce montelukast effectiveness. - Ketoconazole: may elevate montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Beta‑agonists: additive bronchodilatory effect may increase risk of tachycardia.